Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
Rhea-AI Summary
Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on dermatological products, has announced it will report its financial results for Q2 2024 on August 14, 2024, after market close. The company will host a conference call and webcast to discuss these results on August 15, 2024, at 10:00 AM ET.
Investors and interested parties can access the conference call by dialing 1-877-877-1275 (U.S.) or 1-412-858-5202 (international). A webcast of the call will also be available at the provided link. This announcement indicates Biofrontera's commitment to transparency and shareholder communication, allowing stakeholders to gain insights into the company's financial performance and business updates for the second quarter of 2024.
Positive
- Timely reporting of quarterly financial results
- Providing multiple access options for investors (conference call and webcast)
Negative
- None.
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event | Biofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference Call |
Date | Thursday, August 15, 2024 |
Time | 10:00am ET |
Conference Call | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
Webcast | https://event.choruscall.com/mediaframe/webcast.html?webcastid=bU2HFqrt |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on accesswire.com
FAQ
When will Biofrontera Inc. (BFRI) report its Q2 2024 financial results?
What is the date and time of Biofrontera's (BFRI) Q2 2024 earnings conference call?
How can investors access Biofrontera's (BFRI) Q2 2024 earnings call?
What period will Biofrontera's (BFRI) upcoming financial results cover?
